Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France

Completed

• Conditions: Breast Cancer

• Registration Number: NCT00681369
• Lead Sponsor: AstraZeneca

Brief Summary

the purpose of this study is to describe the way Faslodex is used in France, in patients suffering from initial breast cancer, that is to evaluate Faslodex treatment duration and to determine patients profile

Detailed Description

Not available

Study Timeline

• Study Start: 2007-05
• Study Completion: 2007-06
• Study First Submitted: 2008-05-20
• Study First Submitted QC: 2008-05-20
• Study First Posted: 2008-05-21
• Status Verified: 2011-01
• Last Update Submitted: 2011-01-21
• Last Update Posted: 2011-01-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 217

Inclusion Criteria

• Patients suffering from initial breast cancer, treated with Faslodex, treatment which was stopped during 2007

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluate Faslodex therapeutic strategy and treatment duration	At the end of the study
Describe the characteristics of patients treated with Faslodex	At the end of the study